Document is current
Any future updates will be listed below
-
Authors
Axelsson, Torunn
Zetterberg, Henrik
Blennow, Kaj
Arslan, Burak
Ashton, Nicholas J.
Axelsson, Markus
Svensson, Maria K.
Saeed, Aso
Guron, Gregor
-
Funding
Funding for this research was provided by:
University of Gothenburg
- License Information
-
More Information
Article History
Received: 7 December 2024
Accepted: 16 April 2025
First Online: 9 May 2025
Declarations
:
: The Ethics Committee of the University of Gothenburg approved the study (620-07, 2020-05523), and the research was conducted in accordance with the Helsinki Declaration. All study subjects gave informed written consent to participate.
: Not applicable
: TA, BA and AS declare no conflict of interest. MKS and NJA declare no conflict of interest related to this manuscript. GG has given lectures and/or served at scientific advisory boards for Boehringer Ingelheim, AstraZeneca, Bayer, Novo Nordisk, Vifor Pharma, GSK, Sanofi and Otsuka on topics not related to the content of this manuscript. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. MA has received compensation for lectures and/or advisory boards from Biogen, Gazyme and Novartis.
